Suppr超能文献

成纤维细胞生长因子15缺乏对高脂饮食诱导的非酒精性脂肪性肝炎发展的影响。

The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.

作者信息

Schumacher J D, Kong B, Pan Y, Zhan L, Sun R, Aa J, Rizzolo D, Richardson J R, Chen A, Goedken M, Aleksunes L M, Laskin D L, Guo G L

机构信息

Department of Pharmacology and Toxicology, School of Pharmacy, EOHSI, Rutgers University, Piscataway, NJ 08854, United States.

Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.

出版信息

Toxicol Appl Pharmacol. 2017 Sep 1;330:1-8. doi: 10.1016/j.taap.2017.06.023. Epub 2017 Jul 1.

Abstract

Non-alcoholic steatohepatitis (NASH) is a form of non-alcoholic fatty liver disease (NAFLD) characterized by steatosis, inflammation, and fibrosis often associated with metabolic syndrome. Fibroblast growth factor 15 (FGF15), an endocrine factor mainly produced in the distal part of small intestine, has emerged to be a critical factor in regulating bile acid homeostasis, energy metabolism, and liver regeneration. We hypothesized that FGF15 alters the development of each of the listed features of NASH. To test this hypothesis, four-week old male Fgf15 and their corresponding wild-type (WT) mice were fed either a high fat diet (HFD) or a control chow diet for six months. The results confirmed that HFD feeding for six months in WT mice recapitulated human NASH phenotype, including macrovesicular steatosis, inflammation, and fibrosis. Whereas FGF15 deficiency had no effect on the severity of liver steatosis or inflammation, it was associated with decreased liver fibrosis. Furthermore, FGF15 deficiency resulted in abnormal bile acid homeostasis, increased insulin resistance, increased HFD-induced serum triglycerides, decreased inductions of hepatic cholesterol content by HFD, and altered gene expression of lipid metabolic enzymes. These data suggest that FGF15 improves lipid homeostasis and reduces bile acid synthesis, but promotes fibrosis during the development of NASH.

摘要

非酒精性脂肪性肝炎(NASH)是一种非酒精性脂肪性肝病(NAFLD),其特征为脂肪变性、炎症和纤维化,常与代谢综合征相关。成纤维细胞生长因子15(FGF15)是一种主要在小肠远端产生的内分泌因子,已成为调节胆汁酸稳态、能量代谢和肝脏再生的关键因子。我们假设FGF15会改变NASH所列各特征的发展。为验证这一假设,给四周龄雄性Fgf15基因敲除小鼠及其相应的野生型(WT)小鼠喂食高脂饮食(HFD)或对照普通饮食,持续六个月。结果证实,野生型小鼠喂食六个月高脂饮食可重现人类NASH表型,包括大泡性脂肪变性、炎症和纤维化。而FGF15缺乏对肝脏脂肪变性或炎症的严重程度无影响,但与肝脏纤维化减轻有关。此外,FGF15缺乏导致胆汁酸稳态异常、胰岛素抵抗增加、高脂饮食诱导的血清甘油三酯升高、高脂饮食诱导的肝脏胆固醇含量诱导减少以及脂质代谢酶基因表达改变。这些数据表明,FGF15在NASH发展过程中可改善脂质稳态并减少胆汁酸合成,但会促进纤维化。

相似文献

1
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
Toxicol Appl Pharmacol. 2017 Sep 1;330:1-8. doi: 10.1016/j.taap.2017.06.023. Epub 2017 Jul 1.
2
3
Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
PLoS One. 2020 Aug 12;15(8):e0234750. doi: 10.1371/journal.pone.0234750. eCollection 2020.
6
7
Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis.
Hepatology. 2020 Nov;72(5):1586-1604. doi: 10.1002/hep.31167. Epub 2020 Oct 22.
9
Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis.
Cell Mol Gastroenterol Hepatol. 2021;12(3):1001-1019. doi: 10.1016/j.jcmgh.2021.04.013. Epub 2021 May 7.

引用本文的文献

1
Deletion of hepatic FXR leads to more severe MASH development in female mice.
Hepatol Commun. 2025 May 16;9(6). doi: 10.1097/HC9.0000000000000693. eCollection 2025 Jun 1.
2
Effects of intestine-specific deletion of fibroblast growth factor 15 on alcoholic liver disease development in mice.
Liver Res. 2022 May 10;6(2):84-92. doi: 10.1016/j.livres.2022.05.001. eCollection 2022 Jun.
3
Deficiency of Epithelial PIEZO1 Alleviates Liver Steatosis Induced by High-Fat Diet in Mice.
Int J Biol Sci. 2025 Jan 1;21(2):745-757. doi: 10.7150/ijbs.102906. eCollection 2025.
4
Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance.
JCI Insight. 2024 Apr 8;9(7):e174164. doi: 10.1172/jci.insight.174164.
6
Myclobutanil-mediated alteration of liver-gut FXR signaling in mice.
Toxicol Sci. 2023 Feb 17;191(2):387-399. doi: 10.1093/toxsci/kfac129.
9
Fibroblast growth factor 15/19 expression, regulation, and function: An overview.
Mol Cell Endocrinol. 2022 May 15;548:111617. doi: 10.1016/j.mce.2022.111617. Epub 2022 Mar 15.
10
Novel Therapeutic Targets in Liver Fibrosis.
Front Mol Biosci. 2021 Nov 5;8:766855. doi: 10.3389/fmolb.2021.766855. eCollection 2021.

本文引用的文献

1
The Fibroblast Growth Factor signaling pathway.
Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66. doi: 10.1002/wdev.176. Epub 2015 Mar 13.
2
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development.
Int J Cancer. 2015 May 15;136(10):2469-75. doi: 10.1002/ijc.29287. Epub 2014 Nov 6.
4
Fibroblast growth factor 15 deficiency impairs liver regeneration in mice.
Am J Physiol Gastrointest Liver Physiol. 2014 May 15;306(10):G893-902. doi: 10.1152/ajpgi.00337.2013. Epub 2014 Apr 3.
6
NIH Image to ImageJ: 25 years of image analysis.
Nat Methods. 2012 Jul;9(7):671-5. doi: 10.1038/nmeth.2089.
7
Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding.
PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
9
NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages.
Atherosclerosis. 2012 Feb;220(2):287-93. doi: 10.1016/j.atherosclerosis.2011.08.041. Epub 2011 Sep 3.
10
FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway.
Cell Metab. 2011 Jun 8;13(6):729-38. doi: 10.1016/j.cmet.2011.03.019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验